FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies
D. A. Knorr, R. Leidner, S. Jensen, R. Meng, A. Jones, C. Ballesteros-Merino, R. B. Bell, M. Baez, D. Sprott, C. Bifulco, B. D. Piening, R. Dahan, B. Fox, J. Ravetch
This paper identifies FcyRIIB as an inhibitory Fc receptor limiting Treg depletion by anti-CTLA-4 antibodies and shows Fc engineering can enhance their efficacy.
bioRxiv · Jan 19, 2023 · PreprintImmunology